A new concept for the differential diagnosis and therapy of anaemia in cancer patients
- 11 February 2010
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 19 (2) , 261-269
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysisCanadian Medical Association Journal, 2009
- Iron supplementation and erythropoiesis‐stimulatory agents in the treatment of cancer anemiaCancer, 2009
- Characterization and Differentiation of Iron Status in Anemic Very Low Birth Weight Infants Using a Diagnostic NomogramNeonatology, 2008
- Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemiaJournal of Oncology Pharmacy Practice, 2008
- Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin SaturationJournal of the American Society of Nephrology, 2007
- EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 updateEuropean Journal of Cancer, 2007
- EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancerEuropean Journal of Cancer, 2004
- Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized TrialJournal of Clinical Oncology, 2004
- Erythropoietin resistance: the role of inflammation and pro‐inflammatory cytokinesNephrology Dialysis Transplantation, 2002
- Factors determining the percentage of hypochromic red blood cells in hemodialysis patientsKidney International, 1999